Aerie Pharmaceuticals to Host Investor and Media Briefing During the 2015 American Academy of Ophthalmology Annual Meeting on November 13, 2015

-Webcast to Begin at 12:00p.m. Pacific Time-

IRVINE, Calif.--()--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast in conjunction with its Investor and Media Briefing during the 2015 American Academy of Ophthalmology Meeting on Friday, November 13, 2015 at 12:00p.m. PT in Las Vegas, NV.

To view and listen to the webcast please visit our website at http://investors.aeriepharma.com. The webcast will be archived on the Investor Relations section of www.aeriepharma.com and will be available for 30 days following the event.

For more information on the Investor and Media Briefing, please refer to contact information within this press release.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie recently reported the successful results of its second Phase 3 registration trial in the United States named Rocket 2, where the primary efficacy endpoint was to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol. Rocket 3, a 12-month safety-only study, is currently in progress, as is a fourth Phase 3 trial for RhopressaTM, named Rocket 4. Aerie expects to file a new drug application for RhopressaTM with the FDA in the third quarter of 2016. Aerie also completed in 2014 a Phase 2b clinical trial in which RoclatanTM met the primary efficacy endpoint, demonstrating the statistical superiority of RoclatanTM to each of its components, and commenced in September 2015 the first Phase 3 registration trial for RoclatanTM, named Mercury 1. Aerie also recently entered into research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University as it further builds its pipeline for future growth.

Contacts

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Investors
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Media
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

Contacts

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Investors
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Media
Justin Jackson, 212-213-0006
jjackson@burnsmc.com